Determination of paraoxonase (PON1) status requires more than genotyping

Pharmacogenetics

Volumn 9, Issue 6, 1999, Pages 745-753

  Richter, Rebecca J ^a   Furlong, Clement E ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Arylesterase; Diazinon; Diazoxonase; Gulf War Syndrome; Paraoxonase; Parathion; Polymorphism; PON1

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE; CYTOCHROME P450; GLUTAMINE; HIGH DENSITY LIPOPROTEIN; INSECTICIDE;

ADOLESCENT; ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; ASSAY; CORONARY ARTERY DISEASE; DETOXIFICATION; ENZYME BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; HYDROLYSIS; LIPID METABOLISM; LIPID OXIDATION; MALE; NORMAL HUMAN; PARKINSON DISEASE; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL;

EID: 0033461179     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199912000-00009     Document Type: Article

References (56)

1. Adkins S, Can KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human scrum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52:598-608.
2. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98:883-885.
3. Atterberry TT, Burnett WT, Chambers JE. Age-related differences in parathion and chlorpyrifos toxicity in male rats: target and nontarget esterase sensitivity and cytochrome P450-mediated metabolism. Toxicol Appl Pharmacol 1997; 147:411-418.
4. Augustinsson KB, Barr M. Age variation in plasma arylesterase activity in children. Clin Chem Acta 1963; 8:568-573.
5. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different than that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998a; 18:1617-1624.
6. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invent 1998b; 101:1581-1590.
7. Benke GM, Murphy SD. The influence of age on the toxicity and metabolism of methyl parathion und parathion in male and female rats. Toxicol Appl Pharmacol 1975; 31:254-269.
8. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: Identity of K-45 with paraoxonase. Eur J Biochem 1993; 211:871-879.
9. Blatter Garin M-C, James RW, Dussoix P, Blanché H, Passa P, Froguel P. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. J Clin Invest 1997; 99:62-66.
10. Brealey CJ, Walker CH, Baldwin BC. A-esterase activities in relation to the differential toxicity of pirimiphos-methyl to birds and mammals. Pest Sci 1980; 11:546-554.
11. Burnett WT, Chambers JE. Age-related toxicity of the insecticides parathion and chlorpyrifos. Toxicologist 1994; 14:390.
12. Costa LG, Richter RJ, Murphy SD, Omenn GS, Motulsky AG, Furlong CE. Species differences in serum paraoxonase activity correlate with sensitivity to paraoxon toxicity. In: Costa LG, Galli CL, Murphy SD, editors. Toxicology of pesticides: experimental, clinical and regulatory perspectives. Heidelberg: Springer-Verlag; 1987. pp. 263-266.
13. Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, Furlong CE. Serum paraoxonasc and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol 1990; 103:66-76.
14. Costa LG, Li W-F, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interactions 1999; 119-120:429-438.
15. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14:334-336.
16. Dowd JE, Riggs DS. A comparison of estimates of Michaelis-Menten kinetic constants from various linear transformations sources. J Biol Chem 1965; 240:863-869.
17. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35:214-227.
18. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988; 43:230-238.
19. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 1989; 180:242-247.
20. Furlong CE, Li W-F, Costa LG, Richter RJ, Shih DM, Lusis AJ. Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism. Neurotoxicology 1998; 19:645-650.
21. Geldmacher-von Mallinckrodt M, Diepgen TL. The human serum paraoxonase-polymorphism and specificity. Toxicol and Environ Chem 1988; 18:79-196.
22. Harbison RD. Comparative toxicity of some selected pesticides in neonatal and adult rats. Toxicol Appl Pharmacol 1975; 32:443-446.
23. Herrmann SM, Blane H, Poirier O, Arveiler D, Luc G, Evans A, et al. The Gln/Arg polymorphism of human paraoxonase (PON192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 1996; 126:299-303.
24. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human scrum paraoxonase activity polymorphism. Nature Genet 1993; 3:73-76.
25. Kaiser J. Environment institute lays plans for gene hunt. Science 1997; 278:569-570.
26. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998; 141:259-264.
27. Kondo I, Yamamoto M. Genetic polymorphism of paraoxonase I (PON1) and susceptibility to Parkinson's disease. Brain Res 1998; 806:271-273.
28. La Du BN, Furlong, CE, Reiner E. Recommended nomenclature system for the paraoxonases. Chem Biol Interactions 1999; 119-120:599-601.
29. Leviev I, Negro F James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met 54) polymorphism. Arterioscler Thromb Vasc Biol 1997; 17:2935-2939.
30. Li W-F, Costa LG, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993; 40:337-346.
31. Li W-F, Furlong CE, Costa LG, Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 1995; 76:219-226.
32. Li W-F, Costa LG, Furlong CE. Paraoxonase (Pon1) gene in mice: sequencing, chromosomal location, and developmental expression. Pharmacogenetics 1997; 7:137-144.
33. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286:152-154.
34. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129-135.
35. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoprotein in protecting low-density lipoprotein against lipid-peroxidation. Lancet 1997a; 349:851-852.
36. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997b; 122:265-268.
37. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonasc 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidalive modification. FEBS Lett 1998; 423:57-60.
38. Main AR. The role of A-esterase in the acute toxicity of paraoxon, TEPP and parathion. Can J Biochem Physiol 1956; 34:197-216.
39. McElveen J. Mackness M, Colley MC, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32:671-673.
40. Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER, Motulsky AG. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical and linkage studies. Am J Hum Genet 1983; 35:393-408.
41. Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin dependent diabetes mellitus. J Clin Endocrinol and Metabol 1997; 82 2257-2260.
42. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998; 18:1611-1616.
43. Ortigoza-Ferado J, Richter R, Hornung SK, Motulsky AG Furlong CE. Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. Am J Hum Genet 1984; 36:295-305.
44. Pati N, Pati U. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol 1998; 66:165-168.
45. Pope CN, Chakraborti TK, Chapman ML, Farrar JD, Arthun D. Comparison of in vivo cholinesterase inhibition in neonatal and adult rats by three organophosphorothioate insecticides. Toxicology 1991; 68:51-61.
46. Ruiz J, Blanché H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346:869-872.
47. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary artery disease. Artioscler Thromb Vasc Biol 1997; 17:1067-1073.
48. Schmidt H, Schmidt R, Niederkorn K, Gradert A, Schumacher M, Watzinger N, et al. Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis: results from the Austrian Stroke Prevention Study. Stroke 1998; 29:2043-2048.
49. Serrato M, Marian, AJ. A variant of human paraoxonase/ arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96:3005-3008.
50. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639.
51. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-287.
52. Shishido T, Usui K, Sato M, Fukami J-I. Enzymatic conjugation of diazinon with glutathione in rat and American cockroach. Pest Biochem Physiol 1972; 2:51-63.
53. Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Disp 1991; 19:107-112.
54. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, Hashimoto K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996; 57:69-73.
55. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low-density lipoprotein. J Clin Invest 1995; 96:2882-2891.
56. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17:3565-3569.